NASDAQ
TCRR

Tcr2 Therapeutics Inc

(NO DISGNOSTIC SUBSTANCES)
LIFE SCIENCES

Prices are adjusted according to historical splits.

Tcr2 Therapeutics Inc Stock Price

Vitals

Today's Low:
$1.4600
Today's High:
$1.5600
Open Price:
$1.5600
52W Low:
$1.46
52W High:
$7.36
Prev. Close:
$1.5300
Volume:
334017

Company Statistics

Market Cap.:
$0.057 billion
Book Value:
5.86
Revenue TTM:
$0.000 billion
Operating Margin TTM:
0%
Gross Profit TTM:
$0.000 billion
Gross Profit TTM:
$0.000 billion
Profit Margin:
0%
Return on Assets TTM:
-20.4%
Return on Equity TTM:
-41.3%

Company Profile

Tcr2 Therapeutics Inc had its IPO on 2019-02-14 under the ticker symbol TCRR.

The company operates in the LIFE SCIENCES sector and (NO DISGNOSTIC SUBSTANCES) industry. Tcr2 Therapeutics Inc has a staff strength of 0 employees.

Stock update

Shares of Tcr2 Therapeutics Inc opened at $1.56 at the start of the last trading session i.e. 2022-11-02.

The stocks traded within a range of $1.46 - $1.56, and closed at $1.48.

This is a -3.27% slip from the previous day's closing price.

A total volume of 334,017 shares were traded at the close of the day’s session.

In the last one week, shares of Tcr2 Therapeutics Inc have slipped by -26%.

Tcr2 Therapeutics Inc's Key Ratios

Tcr2 Therapeutics Inc has a market cap of $0.057 billion, indicating a price to book ratio of 0.266 and a price to sales ratio of -.

In the last 12-months Tcr2 Therapeutics Inc’s revenue was $0.000 billion with a gross profit of $0.000 billion and an EBITDA of $-0.108 billion. The EBITDA ratio measures Tcr2 Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Tcr2 Therapeutics Inc’s operating margin was 0% while its return on assets stood at -20.4% with a return of equity of -41.3%.

In Q2, Tcr2 Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Tcr2 Therapeutics Inc’s PE and PEG Ratio

Forward PE
-
Trailing PE
-
PEG
None

Its diluted EPS in the last 12-months stands at $-2.805 per share while it has a forward price to earnings multiple of - and a PEG multiple of None. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Tcr2 Therapeutics Inc’s profitability.

Tcr2 Therapeutics Inc stock is trading at a EV to sales ratio of - and a EV to EBITDA ratio of 0.736. Its price to sales ratio in the trailing 12-months stood at -.

Tcr2 Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$0.000 billion
Total Liabilities
$0.000 billion
Operating Cash Flow
$0.000 billion
Capital Expenditure
$0.000 billion
Dividend Payout Ratio
0%

Tcr2 Therapeutics Inc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

Tcr2 Therapeutics Inc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

Tcr2 Therapeutics Inc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, Tcr2 Therapeutics Inc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, Tcr2 Therapeutics Inc paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price
$1.48
52-Week High
$7.36
52-Week Low
$1.46
Analyst Target Price
$12.78

Tcr2 Therapeutics Inc stock is currently trading at $1.48 per share. It touched a 52-week high of $7.36 and a 52-week low of $7.36. Analysts tracking the stock have a 12-month average target price of $12.78.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.

Frequently Asked Questions About Tcr2 Therapeutics Inc

The stock symbol (also called stock or share ticker) of Tcr2 Therapeutics Inc is TCRR

The IPO of Tcr2 Therapeutics Inc took place on 2019-02-14

Similar Industry Stocks ((NO DISGNOSTIC SUBSTANCES))

Last Price
Chg
Chg%
$2.1
-0.09
-4.11%
$0.83
-0.06
-6.68%
$4.6
-0.09
-1.92%
$18.96
-0.51
-2.62%
$0.35
-0
-0.4%

Most Active

Last Price
Chg
Chg%
$58.63
-1.03
-1.73%
$92.12
-4.67
-4.82%
$5.12
-0.61
-10.65%
Apple Inc (AAPL)
$145.03
-5.62
-3.73%
$0.06
0.01
+12.74%

Top Gainers

Last Price
Chg
Chg%
$73
42.7
+140.92%
Oi S.A (OIBR-C)
$0
0
+100%
$0.02
0.01
+100%
$0.25
0.1
+66.44%
$2.85
1.01
+54.86%

Top Losers

Last Price
Chg
Chg%
$5.36
-22.58
-80.82%
$0.02
-0.06
-78.67%
Air T, Inc (AIRTW)
$0.01
-0.03
-75%
$4.51
-5.17
-53.41%
$11.5
-12.2
-51.48%

About

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops new T-cell receptor therapies for cancer patients. The company is headquartered in Cambridge, Massachusetts.

Address

100 BINNEY STREET, CAMBRIDGE, MA, US